HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Adalimumab therapy for Vogt-Koyanagi-Harada syndrome].

AuthorsM Díaz Llopis, L Amselem, F J Romero, S García-Delpech, M L Hernández
JournalArchivos de la Sociedad Espanola de Oftalmologia (Arch Soc Esp Oftalmol) Vol. 82 Issue 3 Pg. 131-2 (Mar 2007) ISSN: 0365-6691 [Print] Spain
Vernacular TitleTratamiento con Adalimumab (nuevo antiTNF) del síndrome de Vogt-Koyanagi-Harada.
PMID17357888 (Publication Type: Case Reports, Letter)
Chemical References
  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Adalimumab
Topics
  • Adalimumab
  • Adult
  • Anti-Inflammatory Agents (administration & dosage, therapeutic use)
  • Antibodies, Monoclonal (administration & dosage, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Humans
  • Injections, Subcutaneous
  • Male
  • Time Factors
  • Treatment Outcome
  • Uveomeningoencephalitic Syndrome (diagnosis, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: